Recently, cases of hepatitis B virus reactivation (HBVr) with direct-acting antiviral therapy (DAAs) for HCV have been reported. However, few data exist from large, Western cohorts. The study objectives were to evaluate the incidence of alanine aminotransferase (ALT) flares, clinically significant hepatic events, and HBVr among a national cohort of US veterans with prior exposure to HBV (anti-HBc+) treated with DAAs. We used a national administrative database to identify patients treated with 
| INTRODUCTION
HBVr with all-oral DAAs in Western populations remain poorly described, the objectives of this study were to evaluate the incidence of alanine aminotransferase (ALT) flares, clinically significant hepatic events, and HBVr among a national cohort of Veterans with evidence of prior exposure to HBV (anti-HBc+) and treated with DAAs. We specifically focused on defining the incidence of clinically significant hepatic events (as HBV DNA is often not serially monitored in clinical practice) and to evaluate post-DAA treatment outcomes.
We hypothesized that clinically significant ALT or HBV flares would be extremely rare among patients with resolved HBV infection (isolated anti-HBc+) and would be more common among patients with chronic HBV (HBsAg+). 
| METHODS

| Study design/cohort identification
| Outcomes
Primary outcomes were as follows: (i) elevations in serum ALT (see below), (ii) clinically significant hepatic events defined as an increase of >100 IU/L of the serum ALT accompanied by an increase of the serum bilirubin level by >2.5 mg/dL, and (iii) 1-log increase in HBV DNA or absolute HBV DNA increase >10 000 IU/mL (4-log), or (iv) HBsAg+ seroreversion (HBsAg− to HBsAg+) while on DAA treatment and for up to 12 months post-DAA treatment. Due to the lack of standardized definitions of ALT "flares," we evaluated several categories which we considered to be clinically significant: twofold and fourfold increases in consecutive ALT values while on DAA therapy (if >30 IU/L) as well as increases to ≥300 and ≥1000 IU/L. Post-treatment outcomes were evaluated for all patients with at least 12 weeks of post-treatment follow-up as well as selecting only patients with no documented HCV relapses (N = 10 595 HIV− HBsAg− subjects) to avoid misclassification of hepatitis flares to HBV in the setting of relapsing HCV. Pharmacy release dates of DAA therapy were used to determine the timing of laboratory values relative to HCV treatment.
| Exposure variables
All demographic and clinical data were obtained from the CDW.
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Laboratory data included serial values of ALT, total serum bilirubin, HCV RNA and HBV DNA (for up to 12 months prior to DAA initiation, while on-treatment, and for up to 12 months post-treatment).
Baseline laboratory values reported were the closest values that preceded the DAA start date; ALT data were available in 99% of cases within 30 days of DAA initiation. Cirrhosis was identified using a previously validated algorithm of at least 1 inpatient or 2 outpa- 
| Statistical analysis
| RESULTS
| Characterization of patient groups
| Baseline and treatment characteristics of HBsAg-, anti-HBc+ patients undergoing hepatitis C virus direct-acting antiviral therapy
The largest group of anti-HBc+ HCV DAA-treated patients were
HBsAg− (N = 17 266). As shown in Table 1 (2) 111 (2) 160 (2) Unknown 976 (6) 412 (6) 564 (6) Genotype, N (%) 1 14 372 (83) 6051 (84) 8321 (82) 2 1444 (8) 560 (8) 884 (9) 3 838 (5) 303 (4) 535 (5) 4-6 171 (1) 64 (1) 107 (1) Cirrhosis, N (%) 4148 (24) 1643 (23) 2505 (25) Decompensated cirrhosis, N (%) 509 (3) 219 (3) 290 ( (10) 958 (9) EBR/GZR 1358 (8) 615 (9) 743 (7) SOF/DAC 242 (1) 87 (1) 155 (2) SOF/LDV 10 737 (62) 4471 (62) 6266 (62) SOF/RBV 1802 (11) 694 (10) 1108 (11) SOF/SMV 914 (5) 363 (5) 551 (5) SOF/VEL 502 (3) 191 (3) 311 (3) HCV DAA duration days, median ( anti-HBs-/unknown subjects. Demographics and treatment characteristics of HIV+ HBsAg− subjects are provided in Table S1 .
| Hepatic events and HBV reactivation rates in HBsAg−, anti-HBc+ patients undergoing hepatitis C virus direct-acting antiviral therapy
We first examined the incidence of ALT elevations during and after antiviral therapy among HIV−, HBsAg− individuals (Table 2) .
During treatment, 2336 (14%) and 577 (3%) developed ALT elevations greater than 2 or 4 times the upper limit of normal (ULN), respectively. ALT elevations greater than 10 times the ULN (≥300 IU/ mL) or ≥1000 IU/mL were rare and occurred in 31 (<0.1%) and 3 (<0.01%), respectively. Only 4 individuals (<0.01%), developed clinically significant hepatic events, defined as an ALT ≥100 IU/mL with (14) 922 (13) 1414 (14) ALT ≥4× ULN, N (%) 577 (3) 236 (3) 341 (3) ALT >300 IU/mL during treatment, N (%) 31 (0) 11 (0) 20 (0) ALT >1000 IU/mL during treatment, N (%)
HBV DNA increase 1-log during therapy, N (%)
Significant hepatic events during therapy, N (%) Following DAA treatment, the frequency of significant ALT elevations ≥300 IU/mL or ≥1000 IU/mL was higher compared to during treatment, occurring in 85 (0.6%) and 10 (0.1%) patients, respectively.
Clinically significant hepatic events occurred in 35 (0.3%) patients, of whom 4 had HCV relapse, 1 had confirmed HBVr, 10 had negative testing for HBV DNA excluding HBVr and 24 did not have HBV-related testing. There were no differences in the incidence of clinically significant hepatic events nor documented HBVr events based on anti-HBs status.
| Hepatic events and HBV reactivation rates in HBsAg+ patients undergoing hepatitis C virus directacting antiviral therapy
A total of 134 HBsAg+ patients not already being treated with HBVsuppressing nucleos(t)ide analogues were treated with HCV DAA during the study period (Table 3) Overall, 13/134 (10%) HBsAg+ patients experienced HBVr during (n = 7) or after therapy (n = 6), clinically significant toxicity was observed in only 1 case who had underlying cirrhosis.
| Characteristics of anti-HBc+ patients with clinically significant hepatic events
Of the entire cohort or 17 779 subjects, 41 (0.2%) developed clinically significant toxicity in the absence of HCV relapse ( 
| HBV reactivation events in anti-HBc+ patients undergoing hepatitis C virus direct-acting antiviral therapy
We identified 17 patients with HBV increases of at least 1-log (and/ or conversion from negative to detectable) during or after antiviral therapy (Table S3 ). This is most likely an underestimate, as baseline testing for HBV DNA was present in only 5% of total cases (Table 2) .
HBVr was documented only in HIV− subjects, 4 of whom were We describe 6 patients with 4-log or greater HBV DNA increases, all but one of whom were HBsAg+ at the start of DAA therapy. Only 1 patient had concomitant clinically significant hepatic events and among the 5 patients with follow-up data, all responded to HBV therapy with decreases in HBV DNA, ALT and total serum bilirubin. When recognized, HBVr was highly responsive to nucleos(t)ide treatment and no serious sequelae could be identified from administrative data.
Overall, the low rates of adverse events we identify in this large
Western cohort are comparable previously published data from China. 12 Although derived from a similar dataset as the previously published data from the VA on HBV reactivation, 13 there are critical differences in our analysis that should be highlighted: (i) the previous analysis only evaluated patients during HCV DAA therapy until 7 days after therapy, likely missing many of the events we identified in longer follow-up of patients; (ii) relied on HBV DNA results which were missing in many patients with hepatitis flares who were not appropriately We postulate that the above strategies may maximize identification of clinically significant HBVr without excessive testing burden, although the specific recommendations regarding the frequency and duration of post-DAA follow-up among those with resolved HBV should be informed by future studies.
